That dosing protocol your friend’s boyfriend found on Reddit? It was designed for a 200-pound man with stable testosterone and no menstrual cycle. Your body operates on different hardware. Here’s why that matters and what to adjust.
Women metabolize peptides differently than men for several interconnected reasons. Estrogen modulates growth hormone secretion — women naturally produce larger, less frequent GH pulses than men. Progesterone affects IGF-1 receptor sensitivity. Body composition differs: women carry higher body fat percentage and lower lean mass, which affects volume of distribution. And hormonal cycles create variable pharmacokinetics that simply don’t exist in male subjects.
Women naturally produce larger GH pulses than men, especially during the luteal phase of the menstrual cycle. Starting doses should typically be lower than male protocols suggest. Many women’s health providers begin CJC-1295/Ipamorelin at 50-75% of standard male dosing and titrate up based on IGF-1 levels at 6-8 weeks.
FDA-approved GLP-1 dosing is not sex-specific — the same titration schedules apply. However, a 2024 Mayo Clinic study showed postmenopausal women on HRT lost 30-35% more weight on semaglutide than those not on HRT. The interaction between estrogen status and GLP-1 response is real and undertested. Women in perimenopause may need slower titration due to nausea sensitivity, which tends to be higher in women.
Standard male dosing (250-500 mcg/day) is often used in women without adjustment. However, no sex-specific pharmacokinetic studies exist. Body weight-adjusted dosing (3-5 mcg/kg) may be more appropriate than flat dosing, especially for smaller women.
Clinical studies in Russia used 900 mcg as the standard dose for both sexes. Anxiolytic effects in women may be more pronounced during the luteal phase when progesterone’s interaction with GABA receptors is highest. Some providers adjust timing to the menstrual cycle for women who are still cycling.
| Peptide | Male “Standard” | Women’s Adjustment | Why |
|---|---|---|---|
| CJC-1295/Ipa | 100/100 mcg nightly | Start 50-75 mcg, titrate to IGF-1 | Higher natural GH pulse amplitude |
| BPC-157 | 250-500 mcg/day | Consider 3-5 mcg/kg body weight | No sex-specific PK data |
| Semaglutide | Standard titration | Same, but slower if nausea-prone | Higher nausea sensitivity in women |
| GHK-Cu (injectable) | 1-2 mg/day | Same range, monitor copper levels | Copper sensitivity varies |
| Selank | 300-900 mcg intranasal | Same, consider cycle timing | GABA interaction varies with progesterone |
Not always, but often. For GH secretagogues, women typically start at 50-75% of male dosing because they naturally produce larger GH pulses. For FDA-approved drugs like semaglutide, dosing is the same. The key is to start conservatively, monitor labs, and adjust based on individual response rather than following generic online protocols.
Yes. Estrogen and progesterone fluctuations throughout the cycle affect GH secretion, GABA receptor sensitivity, insulin sensitivity, and inflammatory responses. Some providers adjust peptide timing or dosing across the cycle. During perimenopause, this variability becomes even more pronounced.
Women experience 1.5-1.7x more adverse drug reactions generally due to differences in body composition, metabolism, and hormonal modulation of drug processing. For peptides specifically, the dosing protocols circulated online were established in male communities and may be too aggressive for female physiology.
There's no established clinical guidance for menstrual cycle-based peptide dosing adjustments. However, some women report increased sensitivity to injection site reactions around menstruation, and anxiety-related symptoms may fluctuate with the cycle. Track your response and discuss patterns with your provider.